Financial Performance - The company's operating revenue for the first half of 2021 was approximately RMB 475.19 million, representing a 19.48% increase compared to RMB 397.70 million in the same period last year[19]. - The net profit attributable to shareholders for the first half of 2021 was approximately RMB 123.12 million, a decrease of 3.79% from RMB 127.96 million in the previous year[19]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was approximately RMB 120.23 million, down 4.70% from RMB 126.17 million in the same period last year[19]. - The net cash flow from operating activities for the first half of 2021 was approximately RMB 92.71 million, a decrease of 3.93% compared to RMB 96.50 million in the previous year[19]. - The total assets at the end of the reporting period were approximately RMB 1.49 billion, an increase of 4.04% from RMB 1.43 billion at the end of the previous year[19]. - The net assets attributable to shareholders at the end of the reporting period were approximately RMB 920.01 million, a decrease of 6.91% from RMB 988.28 million at the end of the previous year[19]. - The basic earnings per share for the first half of 2021 were RMB 0.47, down 4.08% from RMB 0.49 in the same period last year[17]. - The weighted average return on net assets for the first half of 2021 was 12.16%, an increase of 0.09 percentage points compared to 12.07% in the previous year[17]. - The gross profit margin for the industrial biocide business remained high at 45.63%[36]. Cash Flow and Investments - The company’s cash flow from operating activities decreased by 3.93% to CNY 92.71 million[39]. - The company plans to invest CNY 483 million in the Songmu Island Phase III project, with CNY 251.83 million already invested as of June 2021[46]. - The company reported a total cash inflow from financing activities of approximately ¥588.78 million, significantly higher than ¥330.00 million in the same period of 2020[117]. - The total cash outflow from financing activities was ¥594,739,537.19, compared to ¥299,538,567.27, an increase of 98.7%[120]. - The company received ¥398,485,572.00 in borrowings, a substantial increase from ¥30,000,000.00 in the previous period[120]. Market Position and Operations - The company's sales revenue from isothiazolinone industrial biocide raw materials accounted for 98.22% of total consolidated revenue, providing stable cash flow and directly impacting overall profitability and performance[28]. - The total production capacity of the company exceeds 30,000 tons, making it the largest producer of isothiazolinone industrial biocide raw materials in Asia, with plans to exceed 40,000 tons by the end of 2021[29]. - The company has established stable long-term partnerships with major clients such as Dow Chemical and Lanxess, enhancing its competitive advantage in the market[22]. - The company employs a direct sales model, primarily targeting industrial biocide solution providers and traders, ensuring efficient market reach[25]. - The company has established a strong market position with a high market share, benefiting from nearly 20 years of experience in the isothiazolinone industrial biocide market[33]. Research and Development - The company has been recognized as a high-tech enterprise since October 2011, holding multiple invention patents and continuously improving its R&D capabilities[31]. - The company’s R&D expenses increased by 35.74% to CNY 14.41 million, reflecting ongoing innovation efforts[39]. - Research and development expenses for the first half of 2021 were ¥14,409,271.65, compared to ¥10,615,482.28 in the same period last year, representing a 35.5% increase[109]. Environmental and Safety Compliance - The company maintains a strong focus on safety and environmental protection, ensuring compliance with national and local environmental standards[32]. - The company emphasized the importance of environmental protection, facing increased costs due to stricter regulations, which may impact profitability[48]. - Safety production risks are highlighted due to the use of hazardous chemicals, with ongoing efforts to enhance safety training and internal controls[49]. - The company has invested in high-standard environmental protection facilities and personnel to comply with regulations[48]. - The company reported a total of 27.6 tons of chemical oxygen demand (COD) discharged, which is compliant with environmental standards[63]. Shareholder and Governance - A new board of directors and senior management team was elected in April 2021, indicating a leadership change[56]. - The company has committed to respecting the control position of Dalian Baiao Chemical Co., Ltd. by its major shareholder, Sanxin Investment, which will hold shares as a financial investor without seeking control of the company[76]. - The company plans to grant a total of 5.82 million restricted stocks to 64 incentive objects, with an initial grant of 5.52 million shares and a reserved 300,000 shares, at a price of 7.36 CNY per share[59]. - The company has not reported any major litigation or arbitration matters during the reporting period[79]. - The total number of shares after the recent changes is 261,346,400, with 5,461,000 shares being reduced from the unrestricted circulating shares[83]. Risks and Challenges - The report includes a risk statement indicating that future plans and industry trends do not constitute a commitment to investors, highlighting the importance of investment risk awareness[3]. - The company faces industry policy risks related to environmental and safety regulations, which could affect continuous production[50]. - Currency fluctuation risks are significant as international sales constitute a large portion of total revenue, primarily settled in USD[51]. Financial Reporting and Accounting Policies - The company’s financial statements were approved by the board of directors on August 24, 2021[132]. - The company has not identified any significant doubts regarding its ability to continue as a going concern for the next 12 months[136]. - The company’s accounting policies are tailored to its operational characteristics, particularly in areas such as accounts receivable and inventory valuation[137]. - The company recognizes goodwill when the acquisition cost exceeds the fair value of identifiable net assets acquired[146].

Financial Performance - Operating revenue for the first quarter reached CNY 218,397,085.71, a year-on-year increase of 9.37%[7] - Net profit attributable to shareholders decreased by 42.38% to CNY 51,831,316.56 compared to the same period last year[7] - Basic earnings per share fell by 41.18% to CNY 0.20[7] - The weighted average return on equity decreased by 3.11 percentage points to 5.27%[7] - Total operating revenue for Q1 2021 was CNY 218,397,085.71, an increase of 9.6% compared to CNY 199,682,629.30 in Q1 2020[30] - Gross profit for Q1 2021 was CNY 66,584,035.26, compared to CNY 99,569,350.15 in Q1 2020, indicating a decrease in profitability[30] - The net profit for Q1 2021 was CNY 51,831,316.56, representing a decrease of 42.4% from CNY 89,960,059.62 in Q1 2020[32] - The total profit for Q1 2021 was CNY 61,053,791.33, down from CNY 99,771,299.37 in Q1 2020, indicating a decline of 38.8%[31] Assets and Liabilities - Total assets increased by 6.32% to CNY 1,520,021,841.48 compared to the end of the previous year[7] - Total assets as of March 31, 2021, amounted to CNY 1,525,056,004.36, an increase from CNY 1,428,631,511.24 at the end of 2020[27] - Current liabilities totaled ¥480,516,093.42, an increase from ¥396,049,476.04 at the beginning of the period[22] - Total liabilities as of March 31, 2021, were CNY 478,988,620.94, compared to CNY 396,056,440.26 at the end of 2020, indicating increased leverage[27] - Total liabilities amounted to CNY 441,412,764.39, with non-current liabilities totaling CNY 45,363,288.35[43] - Owner's equity stood at CNY 988,283,192.35, with retained earnings of CNY 574,691,374.21[43] Cash Flow - Net cash flow from operating activities decreased by 41.40% to CNY 46,857,098.90[7] - The net cash flow from operating activities for Q1 2021 was CNY 46,857,098.90, a decrease of 41.5% from CNY 79,967,742.71 in Q1 2020[36] - The company experienced a net cash outflow from investing activities of ¥88,964,063.33 in Q1 2021, compared to a net outflow of ¥29,978,644.00 in Q1 2020, indicating a significant increase in investment expenditures[39] - Cash inflow from financing activities was ¥61,873,792.00 in Q1 2021, with a net cash flow from financing activities of ¥16,595,711.30, contrasting with a net outflow of ¥396,700.00 in Q1 2020[39] Shareholder Information - The total number of shareholders at the end of the reporting period was 15,293[13] - The top two shareholders, Dalian Tongyun Investment Co., Ltd. and Dalian Sanxin Investment Co., Ltd., hold 29.00% and 28.00% of shares respectively[13] Research and Development - Research and development expenses surged by 287.55% to ¥6,142,918.54, reflecting significant expenditures on process improvements[16] - Research and development expenses for Q1 2021 were CNY 6,142,918.54, significantly higher than CNY 1,585,064.72 in Q1 2020, reflecting a focus on innovation[30] Operational Costs - Operating costs rose by 62.03% to ¥119,283,001.94, driven by rising raw material prices and the reclassification of certain expenses under new revenue recognition standards[16] - Total operating costs for Q1 2021 were CNY 151,813,050.45, up from CNY 100,113,279.15 in Q1 2020, representing a 51.5% increase[30] Inventory and Asset Management - Inventory levels decreased to CNY 73,251,196.52 from CNY 91,459,227.13 at the end of 2020, indicating improved inventory management[26] - The company reported a significant asset impairment loss of 21,485.33% due to a decline in product prices, resulting in inventory write-downs[16] Other Financial Metrics - Non-recurring gains and losses totaled CNY 1,095,802.21 for the period[10] - The company's trading financial assets decreased by 100% to 0 due to the maturity of structured deposits[15] - Accounts receivable financing decreased by 39.89% to ¥6,412,665.12, attributed to a reduction in receivable notes[15]

Financial Performance - The company's operating revenue for 2020 was CNY 749,541,031.81, a decrease of 14.03% compared to CNY 871,896,072.63 in 2019[20] - The net profit attributable to shareholders for 2020 was CNY 221,754,543.29, down 27.72% from CNY 306,801,352.58 in the previous year[20] - The net profit attributable to shareholders after deducting non-recurring gains and losses was CNY 214,843,244.43, a decrease of 27.81% compared to CNY 297,626,223.40 in 2019[20] - Basic earnings per share decreased by 27.35% to CNY 0.85 in 2020 from CNY 1.17 in 2019[21] - Weighted average return on equity fell by 12.76 percentage points to 20.74% in 2020 from 33.50% in 2019[21] - The company reported a net profit margin of approximately 35.0% for 2020, down from 41.0% in 2019, indicating a decrease in profitability[183] - The total comprehensive income for 2020 was CNY 221,713,080.63, down from CNY 306,929,021.88 in 2019, indicating a decline of 27.77%[185] Cash Flow and Assets - The net cash flow from operating activities for 2020 was CNY 210,615,284.82, down 12.27% from CNY 240,066,206.82 in 2019[20] - The company's cash and cash equivalents increased to CNY 333,068,462.74, compared to CNY 242,123,892.62 in the previous year, marking a growth of approximately 37.6%[176] - Total liabilities rose to CNY 396,056,440.26 in 2020 from CNY 108,250,973.30 in 2019, a significant increase of 266.5%[182] - The company's equity decreased to CNY 1,032,575,070.98 in 2020 from CNY 1,089,165,801.99 in 2019, a decline of 5.2%[182] - The total assets increased to CNY 1,428,631,511.24 in 2020 from CNY 1,197,416,775.29 in 2019, an increase of 19.3%[182] Revenue Breakdown - The company's domestic sales accounted for approximately 53% of total revenue, while international sales made up about 47%, with key markets in Europe, Asia, and North America[31] - The company’s international revenue accounts for nearly half of its total income, primarily from major clients like Dow Chemical and Lanxess[83] - The company reported a total non-current asset value of RMB 818,180,539.83, up from RMB 667,500,104.59 in 2019, indicating a growth of approximately 22.6%[177] Production and Capacity - The company has an annual production capacity of over 30,000 tons of isothiazolinone industrial biocides, with plans to expand capacity to over 40,000 tons by the end of 2021 due to ongoing construction of the Songmu Island Phase III project[41] - The production volume of industrial biocides reached 35,369.77 tons, representing a year-on-year increase of 12.03%, with a capacity utilization rate of 96%[85] - The company has established long-term stable partnerships with major international clients such as Dow Chemical, Lonza, and Lanxess, enhancing its market position[33] Research and Development - Research and development expenses increased by 1.53% to ¥28,569,156.99, accounting for 3.81% of total revenue[55] - The company has 16 invention patents and 8 utility model patents, reflecting its strong R&D capabilities and commitment to technological innovation[36] - Research and development investments over the past three years were 19.15 million RMB, 28.14 million RMB, and 28.57 million RMB, accounting for 3.63%, 3.23%, and 3.81% of revenue respectively, indicating a steady increase[82] Environmental and Safety Compliance - The company has faced environmental protection risks due to its classification as a heavily polluting industry, leading to increased environmental spending and costs[86] - The company has committed to strict adherence to environmental and safety regulations, which may impact continuous production due to potential shutdowns during inspections[86] - The company operates 22 sets of exhaust gas treatment devices, utilizing multi-stage condensation and absorption technology to prevent uncontrolled gas emissions[109] Shareholder Information - The top shareholder, Dalian Tongyun Investment Co., Ltd., holds 75,786,668 shares, representing 29.00% of the total shares[128] - The total number of ordinary shareholders increased to 15,716 by the end of the reporting period[126] - The company has undergone a change in controlling shareholders, with Dalian Tongyun Investment becoming the primary shareholder as of February 7, 2020[131] Management and Governance - The total pre-tax compensation for the board members and senior management during the reporting period amounted to 6.7054 million CNY[144] - The management team has extensive experience in various sectors, including finance, chemical engineering, and corporate management[146] - The company confirmed that there were no significant differences in corporate governance compared to the requirements set by the China Securities Regulatory Commission[161]

2020 年第三季度报告 公司代码：603360 公司简称：百傲化学 大连百傲化学股份有限公司 2020 年第三季度报告 1 / 28 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 7 | | 四、 | 附录 | 10 | 2020 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人刘宪武、主管会计工作负责人王希梁及会计机构负责人（会计主管人员）肖红红 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 3 / 28 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增减 (%) 总资产 1,499,263,652.52 1,189,296,891.60 26.06 归属于上市公司 股东的净资产 ...

Financial Performance - The company's operating revenue for the first half of 2020 was CNY 397.70 million, representing a 13.67% increase compared to CNY 349.89 million in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2020 was CNY 127.96 million, up 13.69% from CNY 112.56 million in the previous year[18]. - The net cash flow from operating activities was CNY 96.50 million, reflecting a 16.27% increase from CNY 82.99 million in the same period last year[18]. - The basic earnings per share for the first half of 2020 was CNY 0.49, an increase of 13.95% compared to CNY 0.43 in the same period last year[20]. - The diluted earnings per share also stood at CNY 0.49, marking a 13.95% increase year-on-year[20]. - The company reported a net profit after deducting non-recurring gains and losses of CNY 126.17 million, which is a 16.20% increase from CNY 108.58 million in the same period last year[18]. - The company's main business saw a revenue of CNY 397.60 million, with a net profit of CNY 121.77 million, marking increases of 15.26% and 10.31% respectively[43]. - The company reported a total comprehensive income of CNY 121,767,091.93 for the first half of 2020, reflecting a significant recovery compared to the previous period[127]. Cash Flow and Assets - The total assets at the end of the reporting period amounted to CNY 1,049,433,564.59, reflecting a stable financial position[122]. - The company's total liabilities increased to CNY 432,846,282.14 as of June 30, 2020, compared to CNY 155,828,392.22 at the end of 2019, marking a significant rise of about 177.5%[98]. - The company's current assets totaled CNY 521,796,787.01 as of June 30, 2020, down from CNY 799,885,203.58 at the end of 2019, indicating a decrease of about 34.8%[96]. - The total cash and cash equivalents at the end of the period amounted to CNY 328,210,197.40, compared to CNY 145,504,299.13 at the end of the first half of 2019, indicating a significant increase of 125.0%[113]. - The company reported a total of CNY 501,928,637.17 in undistributed profits as of June 30, 2020, compared to CNY 485,973,196.59 at the end of 2019, indicating an increase of approximately 3.5%[98]. Research and Development - Research and development expenses increased by 38.30% to CNY 10.62 million, reflecting the company's commitment to innovation[46]. - The company has been recognized as a high-tech enterprise since October 2011, holding multiple invention patents and maintaining a strong R&D team[36]. Market Position and Operations - The main business remains focused on the research, production, and sales of fine chemical products, specifically isothiazolinone-based industrial biocides and the intermediate chemical 2-chlorobenzonitrile (F-nitrile)[25]. - The total production capacity for isothiazolinone-based industrial biocides exceeds 30,000 tons, positioning the company as the largest producer in Asia[34]. - The company has established stable long-term partnerships with major clients such as Dow Chemical and Lanxess, enhancing its market position[32]. - The company’s product range includes CIT/MIT, MIT, OIT, DCOIT, and BIT series, catering to diverse customer needs across various industries[35]. - The company’s sales model is primarily direct sales, targeting industrial biocide solution providers and traders[29]. Environmental Compliance and Safety - The company emphasized its commitment to environmental protection, investing in high-standard facilities and adhering to strict regulations, which may impact profitability[58]. - The company has established a quality management system in accordance with ISO9001 standards, enhancing product quality and market competitiveness[39]. - The company has a wastewater treatment facility with a capacity of 100 tons per day, which processes both production and domestic wastewater, meeting discharge standards[73]. - The company operates a biochemical wastewater treatment facility at Songmu Island with a construction scale of 960 tons per day, currently running at 800 tons per day, achieving compliant discharge[72]. - The company conducts regular third-party monitoring of wastewater and exhaust emissions, ensuring compliance with environmental standards[76]. Shareholder and Capital Structure - The total number of shares increased from 186,676,000 to 261,346,400, with the proportion of listed circulating shares rising to 100%[80]. - The company’s major shareholders have undergone changes, with Dalian Tongyun Investment Co., Ltd. becoming the new controlling shareholder as of February 8, 2020[89]. - The top two shareholders, Dalian Tongyun Investment Co., Ltd. and Dalian Sanxin Investment Co., Ltd., held 29.00% and 28.84% of shares respectively, with significant portions pledged[87]. - The company reported a net asset value per share at 4.02 yuan, up from 3.95 yuan at the end of the previous year, marking a 1.77% increase[82]. Strategic Initiatives - The company is investing CNY 483 million in the third phase of the industrial biocide project, with a construction period of 24 months, expected to commence production in early 2022[44]. - The company faced challenges in export business due to ongoing pandemic conditions in Europe and the US, affecting demand for biocides[43]. - The company faced a decline in market demand due to the COVID-19 pandemic, leading to a strategic shift towards domestic market development to mitigate risks[56]. Financial Liabilities and Investments - The company’s total liabilities at the end of the reporting period were CNY 501,928,637.17, indicating a manageable debt level relative to its equity[122]. - The company has entered into agreements to replace original financial liabilities with new financial liabilities, recognizing the difference between the book value and the consideration paid as current profit or loss[167]. - The company recognizes expected credit losses based on the risk of default, with losses recognized for financial assets measured at amortized cost and those measured at fair value through other comprehensive income[171].

2020 年第一季度报告 公司代码：603360 公司简称：百傲化学 大连百傲化学股份有限公司 2020 年第一季度报告 1 / 20 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 8 | 2020 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | | --- | --- | --- | --- | --- | | | | | 减(%) | | | 总资产 | 1,303,153,051.92 | 1,189,296,891.60 | | 9.57 | | 归属于上市公司 | 1,139,114,008.03 | 1,033,468,499.38 | | 10.22 | | 股东的净资产 | | | | | | | 年初至报告期末 | 上年初至上年报告期末 | 比上年同期增减(%) | | | 经营活动产生的 | 79,967,742.71 | 27,358,318.20 | | 192.30 | | 现金流量净额 ...

Financial Performance - The company's operating revenue for 2019 was CNY 871,896,072.63, representing a 65.08% increase compared to CNY 528,171,162.26 in 2018[21] - The net profit attributable to shareholders for 2019 was CNY 306,801,352.58, which is an increase of 111.31% from CNY 145,187,507.20 in the previous year[21] - The net profit excluding non-recurring gains and losses was CNY 297,626,223.40, up 116.08% from CNY 137,738,034.86 in 2018[21] - Basic earnings per share increased by 110.26% to CNY 1.64 in 2019 compared to CNY 0.78 in 2018[22] - The weighted average return on equity rose to 33.50%, an increase of 13.97 percentage points from 19.53% in 2018[22] - The company achieved a net profit of CNY 31,934,044.93 in Q1 2019, which increased to CNY 121,613,658.42 by Q3 2019[23] - The company reported a total revenue of CNY 137,087,304.22 in Q1 2019, increasing to CNY 270,306,816.79 by Q4 2019[23] - The company reported a total revenue of 1.2 billion in 2019, reflecting a year-over-year growth of 15%[104] - The company reported a total revenue of 2,001.812 million yuan for the year 2019, reflecting a growth of 11.35% compared to the previous year[115] - The company achieved a revenue of 851 million yuan in 2019, representing a year-on-year growth of 75.09%[94] Cash Flow and Assets - Cash flow from operating activities for 2019 was CNY 240,066,206.82, a 77.65% increase from CNY 135,131,582.68 in 2018[21] - Total assets at the end of 2019 reached CNY 1,189,296,891.60, a 32.53% increase from CNY 897,381,513.43 at the end of 2018[21] - Cash and cash equivalents increased significantly to CNY 241,164,711.77 from CNY 54,239,819.48 in 2018, representing a growth of 344%[183] - The company reported a net increase in cash and cash equivalents of CNY 168,635,901.59, contrasting with a decrease of CNY 49,799,842.42 in the previous year[196] - The total cash inflow from operating activities reached CNY 695,961,521.20, up from CNY 458,683,815.63 in the previous year, representing a growth of 51.8%[194] Research and Development - The company's R&D expenses increased by 46.94% to 28,137,898.34 CNY, reflecting a commitment to innovation[46] - Research and development expenses for 2019 amounted to CNY 28,137,898.34, compared to CNY 19,149,686.19 in 2018, indicating a 47% increase[187] - The number of R&D personnel was 69, making up 8.66% of the total workforce, highlighting the company's commitment to innovation[59] - The management team emphasized the importance of technological advancements, with a 10% increase in R&D investment planned for 2020, totaling 120 million RMB[151] Market Position and Products - The company’s main business involves the research, production, and sales of isothiazolinone industrial biocides and chlorobenzonitrile chemical intermediates[29] - The company has established stable long-term partnerships with major clients such as Dow Chemical and Lanxess, enhancing its market position in the industrial biocide sector[34] - The company is the largest producer of isothiazolinone industrial biocides in China, with a significant market share[90] - The company plans to expand its product line by initiating a project for the annual production of 2,000 tons of dye intermediates[44] - The company’s BIT series products have been successfully developed, filling a gap in its product range and allowing for customized services in collaboration with clients[35] Environmental Compliance and Sustainability - The company emphasizes environmental protection and has implemented clean production and recycling concepts in its manufacturing processes, ensuring compliance with environmental standards[36] - The company has reported compliance with environmental regulations, being classified as a key pollutant discharge unit[116] - The company has established a complete environmental management system, with regular monitoring of wastewater and air emissions, ensuring compliance with environmental regulations[127] - The company has committed to social responsibility initiatives, including environmental protection measures, as part of its operational strategy[116] Shareholder and Dividend Information - The company plans to distribute a cash dividend of CNY 6 per 10 shares, totaling CNY 112,005,600, and to increase capital by 4 shares for every 10 shares held[5] - In 2019, the company distributed a cash dividend of 6.00 RMB per 10 shares, totaling 112,005,600.00 RMB, with a net profit distribution ratio of 36.51%[102] - In 2018, the cash dividend was 3.90 RMB per 10 shares, totaling 72,803,640.00 RMB, with a net profit distribution ratio of 50.14%[102] Strategic Outlook and Future Plans - The company provided a future outlook, projecting a revenue growth of 10% for the next fiscal year[104] - The company is actively seeking new fine chemical products to diversify its business structure and mitigate economic risks[93] - The company plans to achieve a revenue of 1 billion yuan in 2020, focusing on stable production and operation of industrial biocides[95] - The company is considering strategic acquisitions to enhance its market position, with a budget of 200 million allocated for potential deals[104] Audit and Compliance - The audit report issued by Da Hua Certified Public Accountants confirmed the accuracy and completeness of the financial statements[4] - The company appointed Dahua Accounting Firm (Special General Partnership) for the 2019 annual audit, with an audit fee of RMB 430,000[108] - There were no major litigation or arbitration matters during the reporting period[109] - The company has no significant changes in accounting policies or estimates during the reporting period[109] Employee and Management Information - The total number of employees in the parent company and major subsidiaries is 797, with 543 in production, 29 in sales, 70 in technology, 16 in finance, and 139 in administration[157] - The total remuneration for directors and senior management was reported at 14,377,000 RMB[149] - The company has a structured approach to assess and determine the remuneration of its senior management[156]

2019 年第三季度报告 公司代码：603360 公司简称：百傲化学 大连百傲化学股份有限公司 2019 年第三季度报告 1 / 22 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 9 | 2019 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人刘宪武、主管会计工作负责人王希梁及会计机构负责人（会计主管人员）刘东光 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度末 | | | --- | --- | --- | --- | --- | | | | | 增减(%) | | | 总资产 | 1, ...

Financial Performance - The company's operating revenue for the first half of 2019 was approximately ¥349.89 million, representing a 38.81% increase compared to ¥252.06 million in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2019 was approximately ¥112.56 million, a significant increase of 78.42% from ¥63.09 million in the previous year[18]. - The net cash flow from operating activities for the first half of 2019 was approximately ¥82.99 million, which is a 13.00% increase compared to ¥73.45 million in the same period last year[19]. - The total assets at the end of the reporting period were approximately ¥1.08 billion, reflecting a 20.68% increase from ¥897.38 million at the end of the previous year[19]. - The net assets attributable to shareholders at the end of the reporting period were approximately ¥911.90 million, which is a 14.08% increase from ¥799.34 million at the end of the previous year[19]. - The basic earnings per share for the first half of 2019 were ¥0.60, up 76.47% from ¥0.34 in the same period last year[20]. - The weighted average return on equity for the first half of 2019 was 13.16%, an increase of 4.37 percentage points compared to 8.79% in the previous year[20]. - The company achieved operating revenue of 349.89 million yuan, a year-on-year increase of 38.81%, and a net profit attributable to shareholders of 112.56 million yuan, up 78.42% compared to the same period last year[34]. Production and Capacity - The company has achieved a total production capacity of 30,000 tons for isothiazolinone industrial biocides following the completion of expansion projects in Q2 and Q3 of 2019[31]. - The production capacity for CIT/MIT series products increased by 12,000 tons/year and BIT series products by 2,500 tons/year, contributing to a significant growth in revenue from the industrial biocide business[36]. - The production of industrial biocides saw a volume increase of 53.87% and a production increase of 53.09% year-on-year, alleviating previous capacity constraints[36]. Research and Development - The company has a robust R&D framework, holding 16 invention patents and 8 utility model patents, which supports its production cost control and product quality assurance[31]. - The company’s R&D expenses increased by 132.38% to 7.68 million yuan, reflecting a greater investment in new processes and products[43]. - Research and development expenses increased to ¥7,675,496.89, up 132.5% from ¥3,302,990.26 in the previous year[102]. Environmental Compliance - The company emphasizes environmental protection and has invested in advanced production and waste treatment facilities to meet national and local standards[31]. - The company reported a chemical oxygen demand (COD) discharge of 1.6613 tons and ammonia nitrogen discharge of 0.3415 tons in the first half of 2019[65]. - The total nitrogen discharge was recorded at 0.6429 tons, with a continuous discharge of sulfur dioxide at 0.11535 tons and nitrogen oxides at 0.3853 tons[65]. - The company has not reported any major environmental violations, demonstrating commitment to sustainability[64]. - The company adheres to the Liaoning Provincial Wastewater Comprehensive Discharge Standard (DB21-1627-2008) for wastewater treatment[67]. Shareholder Information - The company has a total of 8,224 common stock shareholders as of the end of the reporting period[81]. - The top two shareholders, Dalian Sanxin Investment Co., Ltd. and Dalian Tongyun Investment Co., Ltd., each hold 30.00% of the shares, totaling 55,995,034 shares[83]. - The total number of shares held by the top ten unrestricted shareholders amounts to 25,000,000 shares, with the largest individual shareholder being Zhang Zhijian, holding 4,508,519 shares (2.42%)[84]. Financial Position - The company reported a total liability of CNY 171,063,736.68, up from CNY 99,348,013.33, indicating an increase of about 72.1%[95]. - The total equity attributable to shareholders increased to CNY 911,900,163.38 from CNY 799,343,117.50, representing a growth of approximately 14.1%[95]. - The company reported a total of 112,557,286.63 RMB in comprehensive income for the current period[119]. Risk Factors - The company faces risks related to core technology leakage and talent loss, which could adversely affect production and sustainable development[52]. - Environmental protection risks are heightened due to the company's classification as a heavily polluting industry, with potential increases in compliance costs impacting profitability[52]. - The company is facing risks related to the underutilization of production capacity from new projects, which may not reach full production as planned due to various operational challenges[54]. Corporate Governance - The company did not propose any profit distribution or capital reserve transfer to share capital during the reporting period[4]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[6]. - The company has not made any changes to its accounting firm during the audit period, maintaining consistency in financial reporting[61]. Tax Management - The company aims to manage its deferred tax assets and liabilities effectively to optimize tax positions[200]. - The management of deferred tax assets and liabilities is a key component of the company's overall financial strategy[200].

Financial Performance - The company's operating revenue for 2018 was RMB 528,171,162.26, representing a 28.71% increase compared to RMB 410,364,502.50 in 2017[21] - The net profit attributable to shareholders of the listed company reached RMB 145,187,507.20, a 44.80% increase from RMB 100,266,398.87 in the previous year[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 137,738,034.86, up 50.16% from RMB 91,726,600.68 in 2017[21] - Cash flow from operating activities amounted to RMB 135,131,582.68, reflecting a 77.71% increase compared to RMB 76,038,489.56 in the previous year[21] - Total assets at the end of 2018 were RMB 897,381,513.43, a 15.15% increase from RMB 779,330,217.36 at the end of 2017[21] - Net assets attributable to shareholders of the listed company increased to RMB 799,343,117.50, a 16.26% rise from RMB 687,543,010.40 in 2017[21] - Basic earnings per share increased by 39.29% to CNY 0.78 in 2018 compared to CNY 0.56 in 2017[22] - The weighted average return on equity rose to 19.53%, an increase of 4.59 percentage points from 14.94% in 2017[22] - The company achieved operating revenue of CNY 528.17 million and net profit attributable to shareholders of CNY 145.19 million, representing growth of 28.71% and 44.80% respectively compared to 2017[40] - The company achieved a total revenue of CNY 528.17 million in the reporting period, representing a year-on-year growth of 28.71%[46] - The net profit attributable to shareholders was CNY 145.19 million, reflecting a significant increase of 44.80% compared to the previous year[46] Dividend Policy - The company plans to distribute a cash dividend of RMB 3.90 per 10 shares, totaling RMB 72,803,640.00[5] - In 2018, the company distributed cash dividends amounting to 72,803,640 RMB, representing 50.14% of the net profit attributable to shareholders[107] - The cash dividend policy stipulates that at least 20% of the distributable profit should be allocated for dividends when the net profit is positive[105] Operational Highlights - The sales revenue from isothiazolinone-based industrial biocides remains the primary source of income, with an increased contribution from F-cyano intermediates due to partial production from fundraising projects[30] - The CIT/MIT series products are widely used in industrial circulating water and oilfield water injection, contributing significantly to revenue[30] - The industrial biocide business generated revenue of CNY 481.58 million, with a year-on-year growth of 20.02%, while sales volume and production volume increased by 6.90% and 4.47% respectively[40] - The company’s production capacity for isothiazolinone biocides reached 30,000 tons after the completion of the fundraising project, significantly enhancing its market position as the largest producer in China[36] - The company’s comprehensive capacity utilization rate for biocide products reached 98.13%, indicating a supply-demand imbalance that remains a challenge until new capacity is operational[40] - The company has established long-term stable partnerships with international chemical giants such as Dow Chemical and Lanxess, expanding its international sales presence across multiple continents[33] - The company’s BIT series production capability was established with the completion of the fundraising project, enhancing its product portfolio and addressing previous gaps in its offerings[43] - The company’s revenue from the important subsidiary, Shenyang Bai'ao, improved significantly, with losses reduced by CNY 15.43 million compared to the previous year[40] Research and Development - Research and development expenses amounted to CNY 19.15 million, accounting for 3.63% of total revenue, with 67 R&D personnel representing 10.60% of the total workforce[60] - The company holds 15 invention patents and 8 utility model patents, showcasing its commitment to technological innovation and cost control[36] - The company has established a technology center to optimize production processes and develop new products, enhancing its competitive edge in the market[74] Environmental Compliance - The company has a strong focus on environmental protection, ensuring compliance with national and local environmental standards, which is a key competitive advantage[38] - The wastewater treatment facility at Songmu Island subsidiary has a design capacity of 800 tons/day and has been in continuous operation since 2011[131] - The chemical oxygen demand (COD) emissions from Songmu Island subsidiary were 57.1258 tons generated with 3.3502 tons discharged, meeting standards[128] - The total nitrogen emissions from Songmu Island subsidiary were 2.9157 tons generated with 1.0208 tons discharged, meeting standards[128] - The hazardous waste generated at Songmu Island subsidiary included 157.55 tons of distillation residue, with 265.55 tons disposed of[128] - The company has implemented continuous operation of air pollution control facilities since 2011, with a design capacity of 2500 cubic meters/hour for various emissions[131] - The company has successfully completed environmental impact assessments for multiple projects, including the expansion of its CIT/MIT series product line[136] Market Expansion and Strategy - The company aims to expand its international market share, particularly in Europe and North America, where it currently holds a low market share[95] - The company plans to continue expanding its product lines and market presence in the biocide sector[30] - The company’s market expansion strategy includes participation in international trade shows and online marketing to attract new customers[33] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million allocated for potential deals[174] Financial Management - The company has approved the use of up to RMB 100 million of temporarily idle raised funds for cash management[120] - The company also approved the use of up to RMB 100 million of idle self-owned funds for cash management[120] - The company has invested RMB 10 million in bank financial products from raised funds, with an expected annualized return of 4.30%[122] - The company has invested RMB 5 million in self-owned funds in bank financial products, with an expected annualized return of 5.00%[122] Corporate Governance - The company has established a comprehensive compensation management system, ensuring compliance with national and local social security regulations[180] - The company has revised its governance structure and internal control systems in accordance with relevant laws and regulations[185] - The company has maintained a stable management team with no significant changes in personnel during the reporting period[170] - The company reported no changes in shareholding for the current and departing directors, supervisors, and senior management during the reporting period[167] Audit and Compliance - The audit report issued by Ruihua Certified Public Accountants was a standard unqualified opinion[4] - The audit report confirmed that the financial statements fairly reflect the company's financial position and operating results for the year ended December 31, 2018[195] - The audit firm confirmed its independence and adherence to professional ethics while conducting the audit[196] - The company did not have any significant internal control deficiencies reported during the audit period[190] Risks and Challenges - The company faces risks including core technology leakage, environmental protection compliance, and safety production issues[99][100] - The company is under scrutiny for environmental and safety regulations following the explosion, which may affect production operations[102] - The company’s F cyano intermediate and BIT product prices experienced significant fluctuations due to the March 21 explosion incident, impacting future earnings[101]